What Is Stability Testing — And Why It Matters
Stability testing determines whether a pharmaceutical product remains safe and effective throughout its intended shelf life. When a tablet, capsule, injectable, or cream sits on a pharmacy shelf or in a patient’s medicine cabinet, it must retain its potency, purity, and physical integrity from the day it was manufactured to the last day of its stated expiry.
For drug developers, stability testing is not optional. Regulators worldwide — from India’s CDSCO to the US FDA and European EMA — require stability data before a product receives a marketing authorization. Without it, no drug can legally be sold.
For manufacturers already in the market, ongoing stability studies (called “commitment batches”) are mandatory to maintain regulatory compliance and product licenses.
In practical terms, stability testing answers three essential questions:
- How long can this product be stored before it becomes unsafe or ineffective?
- Under what storage conditions must it be kept?
- What degradation products form over time, and do they pose any risk?
ICH Guidelines: The Global Framework for Stability Testing
The International Council for Harmonisation (ICH) publishes the globally accepted framework for pharmaceutical stability testing. The key guidelines are:
ICH Q1A(R2) — Stability Testing of New Drug Substances and Products
This is the foundational guideline. It defines the study design, conditions, testing intervals, and acceptance criteria for new drug submissions. Q1A(R2) specifies three primary storage conditions based on the intended global market:
| Climatic Zone | Condition | Intended Market |
|---|---|---|
| Zone I/II (temperate) | 25°C / 60% RH (long-term) | Europe, US, Japan |
| Zone III (hot dry) | 30°C / 35% RH (intermediate) | Middle East |
| Zone IVa (hot humid) | 30°C / 65% RH (intermediate) | India, Southeast Asia |
| Zone IVb (hot very humid) | 30°C / 75% RH | Brazil, some Asian markets |
India falls in Climatic Zone IVb. Products marketed in India must demonstrate stability at 30°C/65% RH (intermediate) or 40°C/75% RH (accelerated).
ICH Q1B — Photostability Testing
Q1B addresses degradation caused by light exposure. Products must be tested under both UV and visible light to assess whether packaging adequately protects them. This is especially critical for injectables, ophthalmic products, and light-sensitive molecules.
ICH Q1C — Stability Testing for New Dosage Forms
When a company introduces a new strength or form of an already-approved product (e.g., adding a 20mg tablet to an existing 10mg product line), Q1C governs the abbreviated stability requirements.
ICH Q1E — Evaluation of Stability Data
Q1E provides statistical methods for shelf-life estimation from stability data, including how to extrapolate beyond the observed data range. It defines the “regression analysis” approach most regulators require.
Types of Stability Studies
Long-Term Stability Studies
Long-term studies are conducted under conditions matching the intended storage environment. For Zone IVb (India), this means 30°C/65% RH for 12 months minimum (often extended to 24–36 months for a 3-year shelf life claim).
Long-term data is what regulators rely on for final shelf-life determination. Accelerated data can be used to predict long-term behaviour, but cannot replace it.
Accelerated Stability Studies
Accelerated studies stress the product at elevated temperature and humidity — typically 40°C/75% RH — to predict long-term degradation behaviour in a compressed timeframe. ICH Q1A requires 6-month accelerated data as part of initial drug submissions.
If a product shows significant change at 40°C/75% RH during accelerated testing, intermediate condition testing (30°C/65% RH) becomes mandatory.
Intermediate Stability Studies
Conducted at 30°C/65% RH when the 40°C/75% accelerated study shows “significant change.” Significant change is precisely defined by ICH and includes a 5% loss in assay, failure to meet dissolution specifications, exceedance of degradation product limits, or pH failure for liquids.
Photostability Studies
Conducted per ICH Q1B. Samples are exposed to minimum light doses: 1.2 million lux-hours of visible light and 200 watt-hours/m² of UV light. Products failing photostability must be packaged in light-protective containers or sold with amber packaging.
Freeze-Thaw Studies
Required for biologics, vaccines, and products with specific freeze-thaw risks. Multiple cycles of freezing and thawing are performed to assess physical and chemical stability.
Stability Chamber Conditions
NABL-accredited stability chambers maintain precise environmental conditions with continuous data logging. Standard chambers used in pharmaceutical stability testing include:
| Chamber Type | Temperature | Relative Humidity | ICH Application |
|---|---|---|---|
| Long-term (Zone IVb) | 30°C ± 2°C | 65% ± 5% RH | Long-term studies, India-marketed products |
| Accelerated | 40°C ± 2°C | 75% ± 5% RH | Accelerated 6-month studies |
| Refrigerator | 5°C ± 3°C | Uncontrolled | Cold-chain products |
| Freezer | -20°C ± 5°C | Uncontrolled | Biologics, vaccines |
| Photostability | 25°C ± 2°C | 60% ± 5% RH + UV/Vis light | ICH Q1B testing |
All stability chambers must have validated temperature and humidity mapping, alarm systems for excursions, and continuous data loggers with 21 CFR Part 11-compliant software for regulated submissions.
Key Testing Parameters in Stability Studies
Stability studies do not test just one thing. Each time-point pull involves a battery of tests covering multiple quality attributes:
Physical Parameters
- Appearance and colour (visual inspection against standard)
- Hardness, friability, disintegration (for solid dosage forms)
- Viscosity and clarity (for liquids and semi-solids)
- pH (for liquids and injectables)
- Particulate matter (for injectables, per USP <788>)
Chemical Parameters
- Assay (active ingredient content by HPLC or UV spectroscopy)
- Dissolution (how quickly the drug releases from the dosage form)
- Degradation products / related substances (by HPLC)
- Moisture content (by Karl Fischer titration)
- Preservative content (for multi-dose products)
Microbiological Parameters
- Total aerobic microbial count (TAMC)
- Total yeast and mould count (TYMC)
- Specified organisms (E. coli, Salmonella, Staphylococcus aureus)
- Antimicrobial effectiveness testing (for preserved products)
Degradation products receive particular scrutiny. Any unknown degradant above the ICH Q3B identification threshold (0.2% for products with daily dose >1g, 0.1% for lower doses) must be structurally identified and assessed for safety.
Documentation Requirements
Stability studies generate extensive documentation that must meet both GMP and regulatory standards:
Study Protocol: Defines product, batch details, study type, time points, conditions, analytical methods, acceptance criteria, and responsible personnel.
Method Validation: All analytical methods used in stability testing must be validated for specificity, linearity, accuracy, precision, detection limit, and robustness. Stability-indicating methods must demonstrate ability to separate degradants from the active.
Analytical Reports: Each time-point generates a detailed analytical report with raw data, calculations, and conclusions against pre-defined acceptance criteria.
Stability Summary Report: At submission or at shelf-life determination, a compiled summary report presents all data, statistical analysis (per ICH Q1E), proposed shelf life, and recommended storage conditions.
Certificates of Analysis: For each batch and time point, CoAs confirming compliance against specification.
Choosing a Stability Testing Laboratory
When selecting a stability testing partner, pharmaceutical companies and developers should evaluate:
NABL Accreditation: The laboratory’s stability chambers should be covered under its NABL (ISO/IEC 17025) scope. This ensures equipment calibration, personnel competence, and results reliability are independently verified.
Chamber Capacity and Validation: Confirm the lab has adequate chamber space for your batch sizes, and that each chamber has current IQ/OQ/PQ validation documentation.
Software Compliance: For regulated submissions (CDSCO, US FDA, EU), the data acquisition system must comply with 21 CFR Part 11 / EU Annex 11 — electronic records, audit trails, and access controls.
Analytical Capabilities: Stability testing requires HPLC, UV-Vis, Karl Fischer, dissolution, and often LC-MS/MS for degradant identification. Confirm the lab has all required equipment in-house.
Regulatory Track Record: Has the lab’s stability data been accepted in successful ANDA, NDA, or IND submissions? Ask for references.
Turnaround and Communication: Stability studies run for months to years. Choose a partner who communicates proactively about time-point results and any out-of-specification events.
Stability Testing at Auriga Research
Auriga Research operates dedicated stability chambers at our NABL-accredited facilities, covering long-term (30°C/65% RH), accelerated (40°C/75% RH), intermediate, refrigerator, and photostability conditions. Our analytical team has supported stability studies for new drug substances, generics, ayurvedic products, and food supplements.
Our pharmaceutical testing hub supports the full range of stability study types — from early-stage API characterisation to commercial product submissions. If you are planning a stability study or need a quote for your product batch, contact our team.
ICH-compliant study protocols, validated analytical methods, 21 CFR Part 11 data systems, and experienced regulatory scientists — Auriga Research brings the infrastructure your stability program needs.
Auriga Research Team
Auriga Research is India's largest NABL-accredited testing network with laboratories in Delhi, Manesar, Bangalore, Baddi, and Bahadurgarh. Our team of scientists delivers accurate, regulatory-accepted results across pharmaceutical, food, water, environmental, and specialised testing.
About Auriga Research →